PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 25, 2026Hematological OncologyOpen Access

Thrombosis in Low‐Risk Polycythemia Vera: Insights From a Large Real‐World Cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

ICInbar CohenARAlon RozentalPRPia Raanani

Discussion

Loading...

Member takes

Overview

Retrospective cohort study finds significant thrombotic events in low-risk polycythemia vera patients, indicating need for better risk assessment.

Key Points

  • To examine long-term outcomes and thrombotic risks in younger patients with low-risk polycythemia vera.
  • Identified patients aged 18-60 with JAK2-positive PV from Clalit Health Services database.
  • Classified patients without prior thrombosis as low-risk and analyzed clinical characteristics and treatments.
  • Utilized logistic regression to identify predictors of thrombosis.
  • Thrombosis occurred in 17.4% of low-risk patients, predominantly driven by cardiovascular risk factors (OR = 3.10, 95% CI 1.25-7.72; p = 0.015).
  • Cytoreductive therapy was associated with a reduced risk of thrombosis.
  • Secondary malignancies were diagnosed in 16.2%, with prior Hydroxyurea use linked to malignancies (OR = 2.73; 95% CI 1.33-5.61; p = 0.006).

Cite This Study

Cohen et al. (2026) studied this question.

synapsesocial.com/papers/6a13e81d0e02ee3982d32c76https://doi.org/10.1002/hon.70200
View Full Paper
Ask AI
Bookmark
Share